drugset
drugset / Trial / NCT05214222

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT05214222 ↗

Phase 2 Recruiting 100 enrolled Nanfang Hospital, Southern Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.

Timeline

Start
2022-09-02
Primary completion
2026-06-02
Completion
2028-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 10 mg —
Subject Catequentinib Small molecule 12 mg —
Subject Penpulimab Monoclonal antibody 200 mg —
Background Cisplatin Other / unclassified 60 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Paclitaxel Small molecule 135 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous
Background Paclitaxel Small molecule 260 mg/m2 Intravenous

Indications

esophageal squamous cell carcinoma